A joint US Food and Drug Administration advisory committee has voted against approving a novel drug for acute pain that combines hydrocodone, acetaminophen, and promethazine.
Following the Feb. 16 deadline for submitting new legislation to be considered for enactment this year, CLSA expects to see more than a dozen bills related to opioids when the dust settles. Though most of those bills dealt with monitoring prescriptions and other largely administrative issues for prescribers, one such recently introduced bill has CLSA concerned.
Life expectancy in the U.S. fell for the second year in a row in 2016, nudged down again by a surge in fatal opioid overdoses, federal officials report Thursday.
The first hints of the potential for cone snail venom emerged a few decades ago when Baldomero Olivera completed his postdoctoral studies at Stanford University and returned home to the Phillipines in 1968. Upon arrival, he was shocked to find a sparsely equipped lab and a lack of the tools and reagents to which he had grown accustomed. After wracking his brains to find a research project he could do in his new lab, he finally settled on determining how cone snails—which were prevalent in the Phillipines—killed. “I thought this would be a short-term project, and that after a while, I could return to DNA replication,†he said in a seminar. Over the next 25 years, Olivera and numerous collaborators studied ω-conotoxin MVIIA inside and out, hoping to take advantage of its localization to pain circuits. They tested every possible modification and alteration, and studied its structure, function, and the locations of the receptors it bound in mice and humans. Finally, in December 2004, the FDA approved ω-conotoxin MVIIA—synthetically produced, but in the exact form made by the snail—as a pain-relieving drug. “If you’re going to sell something as a drug, ω-conotoxin is not exactly the best name,†Olivera said. “Today, this drug is called Prialt, which is primary alternative to morphine.â€
EDITOR'S NOTE: Expanesthetics is among many companies developing non-opioid analgesics. Sometimes news about discoveries can be a bit sensationalized and oversimplified. Here's a narrative that illuminates the ardor involved in developing a drug product to treat pain. Like the discovery in this story , Expanesthetics is also currently working on a drug that might eventually be able to treat chemotherapy induced neuropathy.
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) approved Zilrettaâ„¢ (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain. Zilretta is a non-opioid medicine that employs Flexion's proprietary microsphere technology to provide proven pain relief over 12 weeks.